Eli Lilly's success rate in clinical trials was phenomenal last year. The drugmaker has made a big name for itself in diabetes and weight loss. But it's also proving innovative even beyond its core ...
Feb 12 (Reuters) - Eli Lilly (LLY.N), opens new tab had $1.5 billion worth of pre-launch inventory of its experimental oral weight-loss drug, a filing showed on Thursday, ahead of an expected decision ...
Feb 9 (Reuters) - Eli Lilly (LLY.N), opens new tab will buy Orna Therapeutics for up to $2.4 billion in cash, gaining access to a technology that allows patients' own cells to generate therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results